The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.
The company has acquired the rights from an Austrian firm that has made a vital contribution to the development of new approaches to treating the disease.
The core element of the platform technology involves human proteins which – despite offering sufficient functionality – are subjected to enzymatic digestion in untreated cells due to genetic mutations in their structure.
Axentis Pharma AG (Switzerland) today announced that, as part of its takeover of an Austrian research company, it has also acquired two patent families that incorporate a series of international patent applications.
The company is taking over these rights from Austrian-based BioDevelops Pharma GmbH, which three years ago identified the therapeutic potential offered by a new approach to the treatment of cystic fibrosis and secured the relevant rights.
Joerg Zielasek, president of Axentis Pharma AG, said: “By acquiring the rights to BioDevelops’ technology platform, Axentis Pharma is both enhancing its development pipeline and offering both patients and investors extensive prospects for the treatment of this disease.”